BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

2:30 PM
 | 
Dec 12, 2016
 |  BC Week In Review  |  Clinical News  |  Regulatory

Relvar Ellipta regulatory update

GlaxoSmithKline and Innoviva (formerly Theravance Inc.) said Japan approved an expanded label for Relvar Ellipta fluticasone furoate/vilanterol to include treatment of chronic obstructive pulmonary disease (COPD) when concurrent use of an inhaled corticosteroid and...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >